皮肌炎的小分子药物治疗研究进展

Research Progress in Small-Molecule Drug Therapy for Dermatomyositis

皮肌炎是一种特发性炎症性的累及皮肤或肌肉系统的疾病,具有特征性的皮肤表现和(或)对称性四肢近端肌肉无力症状。年龄和性别标准化的皮肌炎的患病率为每100,000名成人28.6例,平均年发病率为每100,000名成人有2.8~3.0例。皮肌炎相关药物使用率从诊断后第一年的73%下降到第八年的46%。糖皮质激素是最常用的药物类别,但仍有许多病人经上述治疗无效,发展为难治性皮肌炎。该研究就生物制剂及JAK抑制剂在皮肌炎中的应用进展进行综述,以期为皮肌炎的临床治疗提供参考。

Dermatomyositis is an idiopathic inflammatory disease involving the skin or muscle system, with characteristic skin manifestations and (or) symmetrical muscle weakness proximal to the extremi-ties. The prevalence of age- and sex-standardised dermatomyositis was 28.6 cases per 100,000 adults, with an average annual incidence of 2.8~3.0 cases per 100,000 adults. Dermomyositis-rela- ted drug use decreased from 73% in the first year after diagnosis to 46% in the eighth year. Gluco-corticoids are the most commonly used drug class, but many patients still develop refractory der-matomositis. This study summarizes the application progress of biological agents and JAK inhibitors in dermatomositis, in order to provide a reference for the clinical treatment of dermatomyositis.